The Prevalence of Methylenetetrahydrofolate Reductase 677 C-T,Factor V 1691 G-A,and Prothrombin 20210 G-A Mutations in Healthy Populations in Sétif,Algeria
Free accessResearch articleFirst published online October, 2009
The Prevalence of Methylenetetrahydrofolate Reductase 677 C-T,Factor V 1691 G-A,and Prothrombin 20210 G-A Mutations in Healthy Populations in Sétif,Algeria
The polymorphic mutation 677 C-T in the methylenetetrahydrofolate reductase (MTHFR) gene presents a heterogeneous worldwide distribution and is associated with different disorders such as cardiovascular disease. Its frequency shows great ethnic and geographic variations. The aim of this work is to determine the frequency of MTHFR 677 C-T and coexistence of MTHFR 677 C-T with 2 other common, hereditary thrombophilia causes—namely, factor V 1691 G-A and prothrombin (PT) 20210 G-A mutation—in the Sétif region of Algeria. The study involved 147 apparently healthy participants (82 men and 65 women). Genotyping was carried out by a real-time polymerase chain reaction. The MTHFR 677T carrier frequency was found to be 54.4% (80/147); 59 individuals were heterozygous (40.1%), and 21 were homozygous (14.3%). The frequency of MTHFR 677T was found to be 34.3%. Among the 147 individuals, 3 (2.0%) had factor V Leiden, and 5 (3.4%) had PT 20210 A mutation. Of the 80 participants with MTHFR 677T mutation, 2 had heterozygote factor V 1691 G-A gene mutation, and 4 had heterozygote PT 20210 G-A gene mutation. The results showed that MTHFR 677T prevalence is quite high: an allelic frequency of 34.3% with a genotype frequency of 14.3%. Factor V 1691 G-A and PT 20210 G-A gene mutations are rare in the healthy population of the Sétif region of Algeria.
Bertina RM, Koeleman BPC, Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
2.
Poort SR, Rosendaal FR, Reitsma PH, Bertina RMA common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
3.
Couturaud F. , Oger E., Abalain JH, et al. Methylenetetrahydrofolate reductase C677T genotype and venous thrombo-embolic disease. Respiration . 2000; 67:657-661.
4.
Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ III.Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998; 158:585-593.
5.
Hagstrom JN, Walter J., Bluebond-Langner R., Amatniek JC, Manno CS, High KAPrevalence of the factor V Leiden mutation in children and neonates with thromboembolic disease. J Pediatr. 1998 ;133:777-781.
Hira B., Pegoraro RJ, Rom L., Moodley J.Absence of factor V Leiden, thrombomodulin and prothrombin gene variants in Black South African women with pre-eclampsia and eclampsia. BJOG. 2003;110:327-328.
8.
Abdulkadir J. , Feleke Y., Berg JP, Falch JA, Odegaard ORAbsence of the factor V Leiden mutation in Ethiopians. Thromb Res. 1997;86:181-182.
9.
Arnutti P., Nathalang O., Cowawintaweewat S., Prayoonwiwat W., Choovichian P.Factor V Leiden and prothrombin G20210 mutations in Thai patients awaiting kidney transplant. Southeast Asian J Trop Med Public Health . 2002;33:869-871.
10.
Kim TW, Kim WK, Lee JH, et al. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep venous thrombosis . J Korean Med Sci. 1998;13: 587-590.
11.
Lu Y., Zhao Y., Liu G., et al. Factor V gene G1691A mutation, prothrombin gene G20210A mutation, and MTHFR gene C677T mutation are not risk factors for pulmonary thromboembolism in Chinese population. Thromb Res. 2002;106:7-12.
12.
Irani-Hakime N., Tamim H., Kreidy R., Almawi WYThe prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese. Am J Hematol.2000;65: 45-49.
13.
Tamim H., Finan RR, Almawi WYPrevalence of two thrombophilia predisposing mutations: factor V G1691A (R506Q; Leiden) and prothrombin G20210A, among healthy Lebanese. Thromb Haemost. 2002;88: 691-692.
14.
Akar N., Akar E., Dalgin G., et al. Frequency of factor V 1691 G-A mutation in Turkish population . Thromb Haemost. 1997;78:1527.
15.
Angelopoulou K., Nicolaides A., Constantinou Deltas C.Prevalence of genetic mutations that predispose to thrombophilia in a Greek Cypriot population . Clin Appl Thromb Hemost. 2000;6:104-107.
16.
Italian Study Group.Atherosclerosis, Thrombosis, and Vascular Biology. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infraction at a young age. Circulation. 2003;107:1117-1122.
17.
Lopaciuk S. , Bykowska K., Kwiecinski H., et al. Factor V Leiden, prothombin gene G20210A variant, and methylenetetrahydrofolate reductase C677T genotype in young adults with ischemic stroke. Clin Appl Thromb Hemost. 2001;7:346-350.
18.
Coen D., Zadro R., Honovic L., Banfic L., Stavljenic Rukavina A.Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism. Croat Med J. 2001;42:488-492.
19.
Aznar J., Vaya A., Estelles A., et al. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives . Haematologica. 2000;85:1271-1276.
20.
Brown K., Luddington R., Baglin T.Effect of the MTHFR C677T variant on risk of venous thromboembolism: interaction with factor V Leiden and prothrombin (F2G20210A) mutations. Br J Haematol. 1998;103: 42-44.
21.
Brugada R., Marian AJA common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infraction. Atherosclerosis. 1997;128:107-112.
22.
Brattström MD, Wilcken DEL, Öhrvik J., Brudin L.Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the results of a meta-analysis. Circulation. 1998 ;98:2520-2526.
23.
Fletcher O. , Kessling AMMTHFR association with artheriosclerotic vascular disease. Hum Genet. 1998; 103:11-21.
24.
Benabadji M. , Chamla MCLes groupes sanguins ABO et rhésus des algériens. Anthropologie. 1971 ;75:427-442.
25.
Bosch E., Calafell F., Perez-Lezaun A., Comas D., Mateu F., Bertranpetit J.Population history of North Africa: evidence from classical genetic markers . Hum Biol. 1997;69:295-311.
26.
Franco RF, Araujo AG, Guerreiro JF, Elion J., Zago MAAnalysis of 677C→T mutation of the methylenetetrahydrofolate reductase gene in different ethnic groups. Thromb Haemost . 1998;79:119-121.
27.
Stevenson RE , Schwartz CE, Du YZ, Adams MJ Jr.Differences in methylenetetrahydrofolate reductase genotype frequencies between Whites and Blacks. Am J Hum Genet. 1997;60:229-230.
28.
Arruda VR, Siqueira LH, Goncalves MS, et al. Prevalence of the mutation 677C→T in the methylenetetrahydrofolate reductase gene among distinct ethnic groups in Brazil. Am J Med Genet. 1998;78: 332-335.
29.
Camacho-Vanegas O., Giusti B., Restrepo Fernandez CM, Abbate R., Pepe G.Frequency of factor V (FV) Leiden and C677T methylenetetrahydrofolate reductase (MTHFR) mutations in Colombians. Thromb Haemost.1998;79:883-884.
30.
de Franchis R., Mancini FP, D’Angelo A., et al. Elevated total plasma homocysteine and 677C→T mutation of the 5,10-methylenetetrahydrofolate reductase gene in thrombotic vascular disease. Am J Hum Genet.1996;59: 262-264.
31.
Schneider JA , Rees DC, Liu YT, Clegg JBWorldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet. 1998;62: 1253-1260.
32.
Rosen E., Renbaum P., Heyd J., Levy-Lahad E.High frequency of factor V Leiden in a population of Israeli Arabs . Thromb Haemost.1999;82:1768.
33.
Guillen M., Corella D., Portoles O., Gonzalez JI, Mulet F., Saiz C.Prevalence of the methylenetetrahydrofolate reductase 677C>" xbd="538" xhg="517" ybd="2740" yhg="2718"/>T mutation in the Mediterranean Spanish population. Association with cardiovascular risk factors. Eur J Epidemiol.2001;17:255-261.
34.
Jerbi Z., Abdennebi M., Douik H., et al. Etude du polymorphisme C677T du gène de la méthylène tétrahydrofolate réductase dans la population tunisienne. Ann Biol Clin. 2005;63:487-491.
35.
Ameen G., Irani-Hakime N., Fawaz NA, Mahjoub T., Almawi WYAn Arab selective gradient in the distribution of factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T . J Thromb Haemost. 2005;3:2126-2127.
36.
Pollak RD, Friedlander Y., Pollak A., Idelson M., Bejarano-Achache I., Blumenfeld A.Ethnic differences in frequency of the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene in healthy Israeli Populations. Genet Test. 2000;3:309-311.
37.
Ivanova R., Astrinidis A., Djoulah S., et al. Mitochondrial DNA polymorphisms of a west Algerian population (Oran region). Biomed Pharmacother. 1999;53:386-392.
38.
Helley D., Chafa O., Yaker NL, Reghis A., Fischer A-M.Prevalence of the prothrombin gene 20210A mutation in thrombophilic and healthy Algerian subjects. Thromb Haemost. 1999;82:1554-1555.
39.
Ulu A., Elsobky E., Elsayed M., Yildiz Z., Tekin M., Akar N.Frequency of five thrombophilic polymorphisms in the Egyptian population . Turk J Hematol. 2006;23:100-103.
40.
Gurgey A., Mesci L.The prevalence of factor V Leiden (1691G-A) mutation in Turkey. Turk J Pediatr. 1997;39: 313-315.
41.
Kabukcu S., Keskin N., Keskin A., Atalay E.The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylenetetrahydrofolate reductase C677T gene mutation in healthy population of Denizli, Aegean region of Turkey . Clin Appl Thromb Hemost. 2007;13:166-171.
42.
Kurt C., Tanriverdi K., Kocak R.The frequency of factor V Leiden in southern Turkey. Ann Med Sci. 1999;8:56.
43.
Vurkun M., Vural Ö., Demir M.The prevalence of activated protein C resistance and F V Leiden in healthy population of Edirne, Turkey. Turk J Hematol.2002;19: 287-291.
44.
Awidi A., Shannak M., Bseiso A., et al. High prevalence of factor V Leiden in healthy Jordanian Arabs . Thromb Hemost. 1999;81:582-584.
45.
Grandone E. , Margaglione M., Colaizzo D., et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost . 1997;77:822-824.
46.
Lucotte G., Mercier G.Population genetics of factor V Leiden in Europe. Blood Cells Mol Dis. 2001;27:362.
47.
Lefevre-Witier P., Aireche H., Benabadji M., et al. Genetic structure of Algerian populations . Am J Hum Biol.2006;18:492-501.
48.
Kluijtmans LAJ , van den Heuvel Lpwj, Boers GHJ, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996;58:35-41.
49.
Kluijtmans LAJ , Den Heijer M., Reitsma PH, Heil SG, Blom HJ, Rosendaal FRThermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost. 1998;79: 254-258.
50.
Den Heijer M. , Lewington S., Clarke R.Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005;3:392-399.
51.
Torres JD, Cardona H., Alvarez L., et al. Inherited thrombophilia is associated with deep vein thrombosis in a Colombian population. Am J Hem. 2006;81:933-937.
52.
Ma J., Stampfer MJ, Giovannucci E., et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res. 1997;57:1098-1102.
53.
Rosenberg N. , Murata M., Ikeda Y., et al. The frequent 5,10-Methylenetetrahydrofolate reductase C677T polymorphism is associated with a common haplotype in Whites, Japanese, and Africans. Am J Hum Genet. 2002 ;70: 758-762.
54.
Chafa O., Reghis A., Aubert A., Fisher AMPrevalence of the FVQ506 (Factor V Leiden) mutation in the normal and thrombophilic Algerian population. Br J Haematol. 1997;97:688-689.
